$2,070,000 of ELEVANCE HEALTH INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"ACA Exchanges & Enrollment Enhanced Premium Tax Credits The Lower Health Care Premiums for All Americans Act (H.R. 6703) Prior Authorization Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (118th Congress) Site-based Invoicing and Transparency Enhancement (SITE) Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health Veterans Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025 (S. 275 and H.R. 7040) Veterans Affairs Community Cares program GUARD Veterans Health Care Act (H.R. 4077) Provider Directories Transparency in Coverage and Machine-Readable Files Patients Deserve Price Tags Act (H.R. 5582 & S. 2355) No Surprises Act Implementation No Suprises Act Enforcement Act (H.R. 4710) Physician Led and Rural Access to Quality Care Act (H.R. 2191) One Big Beautiful Bill Act (H.R. 1) Consolidated Appropriations Act of 2026 (H.R.7148) ACA Exchanges & Enrollment Enhanced Premium Tax Credits The Lower Health Care Premiums for All Americans Act (H.R. 6703) Prior Authorization Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (118th Congress) Site-based Invoicing and Transparency Enhancement (SITE) Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health Veterans Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025 (S. 275 and H.R. 7040) Veterans Affairs Community Cares program GUARD Veterans Health Care Act (H.R. 4077) Provider Directories Transparency in Coverage and Machine-Readable Files Patients Deserve Price Tags Act (H.R. 5582 & S. 2355) No Surprises Act Implementation No Suprises Act Enforcement Act (H.R. 4710) Physician Led and Rural Access to Quality Care Act (H.R. 2191) One Big Beautiful Bill Act (H.R. 1) Consolidated Appropriations Act of 2026 (H.R.7148) Medicare Advantage Supplemental Benefits In-Home Health Risk Assessments and Chart Review The Apples-to-Apples Comparison Act (H.R. 4093 & S. 3848) No UPCODE Act Puerto Rico Medicaid Program Funding - Federal Matching Assistance Percentage (FMAP) Puerto Rico Medicare Program Funding Medicare Advantage & Medicare Part D Prescription Drug Program Medicaid Managed Care Medicaid Eligibility and Redetermination Medicare Site Neutrality Medicare & Medicaid Social Determinants of Health (SDOH) Medicare Advantage - 2027 CMS Advance Rate Notice for MA and Parts D program Medicare Administrative Contractor Local Coverage Determination (LCD) Process One Big Beautiful Bill Act (H.R. 1) Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) One Big Beautiful Bill Act (H.R. 1) Consolidated Appropriations Act of 2026 (H.R.7148)"
You can find more data on corporate lobbying on Quiver Quantitative.
ELV Congressional Stock Trading
Members of Congress have traded $ELV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ELV Insider Trading Activity
ELV insiders have traded $ELV stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:
- CHARLES MORGAN JR KENDRICK (EVP & President, Commercial) sold 3,196 shares for an estimated $910,604
- STEVEN H COLLIS purchased 3,000 shares for an estimated $869,519
- AMY W SCHULMAN sold 26 shares for an estimated $7,475
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ELV Hedge Fund Activity
We have seen 630 institutional investors add shares of ELV stock to their portfolio, and 778 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,196,465 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $2,522,720,805
- WELLINGTON MANAGEMENT GROUP LLP added 1,668,679 shares (+25.2%) to their portfolio in Q4 2025, for an estimated $584,955,423
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,607,274 shares (+27.5%) to their portfolio in Q4 2025, for an estimated $563,429,900
- HARRIS ASSOCIATES L P added 1,604,821 shares (+50.3%) to their portfolio in Q4 2025, for an estimated $562,570,001
- CAPITAL INTERNATIONAL INVESTORS removed 1,367,274 shares (-46.3%) from their portfolio in Q4 2025, for an estimated $479,297,900
- INVESCO LTD. added 1,306,390 shares (+50.3%) to their portfolio in Q4 2025, for an estimated $457,955,014
- CITADEL ADVISORS LLC added 1,244,783 shares (+294.1%) to their portfolio in Q4 2025, for an estimated $436,358,680
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELV Analyst Ratings
Wall Street analysts have issued reports on $ELV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 01/30/2026
- Wells Fargo issued a "Overweight" rating on 01/30/2026
- TD Cowen issued a "Buy" rating on 11/26/2025
- Mizuho issued a "Outperform" rating on 11/04/2025
- JP Morgan issued a "Overweight" rating on 10/28/2025
To track analyst ratings and price targets for ELV, check out Quiver Quantitative's $ELV forecast page.
ELV Price Targets
Multiple analysts have issued price targets for $ELV recently. We have seen 12 analysts offer price targets for $ELV in the last 6 months, with a median target of $391.0.
Here are some recent targets:
- David Windley from Jefferies set a target price of $391.0 on 04/20/2026
- David Macdonald from Truist Securities set a target price of $375.0 on 04/13/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $345.0 on 04/08/2026
- Ann Hynes from Mizuho set a target price of $350.0 on 03/11/2026
- Lisa Gill from JP Morgan set a target price of $397.0 on 02/02/2026
- Andrew Mok from Barclays set a target price of $393.0 on 01/30/2026
- Stephen Baxter from Wells Fargo set a target price of $391.0 on 01/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
